Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO) - Effect of ranibizumab in eyes with macular edema associated with CRVO

Ophthalmology, Mie University Hospital0 sites30 target enrollmentJanuary 10, 2014

ConditionsCentral retinal vein occlusion

Overview

Phase: N/A
Intervention: Not specified
Conditions: Central retinal vein occlusion
Sponsor: Ophthalmology, Mie University Hospital
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 10, 2014

End Date

January 31, 2016

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Ophthalmology, Mie University Hospital

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Any history of previous treatments for CRVO

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

N/A

A study of factors which predicts the therapeutic effect of acotiamide on abdominal symptoms in patients with Functional dyspepsia.Functional dyspepsia

JPRN-UMIN000036265Akita University Graduate School of Medicine Department of Gastroenterology and Neurology200

Completed

N/A

Prognostic Factors for treatment and follow-up of patients after colorectal surgerychemo- en radiotherapeutische voorbehandelingseffecten op maagdarm neoplasmatacolorectal cancergut cancer1001799110017998

NL-OMON31685Atrium Medisch Centrum400

Completed

Phase 3

Study on indicators for predicting the therapeutic effect of SGLT2 inhibitors under actual clinical practice in T2DM patientstype 2 diabetes mellituds

JPRN-UMIN000032848Osaki Citizen Hospital100

Completed

N/A

A preliminary study of a predictor of treatment response to transcranial magnetic stiumulation in treatment-resistant depressio

JPRN-UMIN000026122Teikyo University15

Completed

N/A

To know the outcome of specially prepared blood derivative on treatment of decay of bone due to certain cancer medicines commonly termed as MRONJ (Medicine related osteonecrosis of jaw)Health Condition 1: null- malignant disease and bony metastases receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and Denosumab

CTRI/2017/09/009615no269